Uses of DHEA in aging and other disease states

被引:59
作者
Johnson, MD [1 ]
Bebb, RA [1 ]
Sirrs, SM [1 ]
机构
[1] Univ British Columbia, Div Endocrinol, Vancouver, BC V5Z 1C6, Canada
关键词
DHEA; AIDS; cancer; aging; cardiovascular disease;
D O I
10.1016/S0047-6374(01)00369-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Dehydro-3-epiandrosterone is a steroid hormone synthesized in large quantities by the adrenal gland whose physiologic role remains unclear. The effects of DHEA could be estrogenic or androgenic, depending on the hormonal milieu. Low levels of DHEA are associated with aging, cardiovascular disease in men, and an increased risk of premenopausal breast and ovarian cancer. High levels of DHEA might increase the risk of postmenopausal breast cancer. Therapeutically DHEA might be useful for improving psychological well-being in the elderly, reducing disease activity in people with mild to moderate systemic lupus erythernatosus and myotonic dystrophy, improving mood in those clinically depressed, and improving various parameters in women with adrenal insufficiency. Although many other claims have been made for DHEA in diverse conditions, such as aging, dementia, and AIDS, no well-designed clinical trials have clearly substantiated the utility and safety of long-term DHEA supplementation. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 41
页数:13
相关论文
共 63 条
[41]   DEHYDROEPIANDROSTERONE REDUCES SERUM LOW-DENSITY LIPOPROTEIN LEVELS AND BODY-FAT BUT DOES NOT ALTER INSULIN SENSITIVITY IN NORMAL MEN [J].
NESTLER, JE ;
BARLASCINI, CO ;
CLORE, JN ;
BLACKARD, WG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 66 (01) :57-61
[42]   UP-REGULATION OF HIGH-AFFINITY DEHYDROEPIANDROSTERONE BINDING-ACTIVITY BY DEHYDROEPIANDROSTERONE IN ACTIVATED HUMAN T-LYMPHOCYTES [J].
OKABE, T ;
HAJI, M ;
TAKAYANAGI, R ;
ADACHI, M ;
IMASAKI, K ;
KURIMOTO, F ;
WATANABE, T ;
NAWATA, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (10) :2993-2996
[43]   AGE-CHANGES AND SEX-DIFFERENCES IN SERUM DEHYDROEPIANDROSTERONE SULFATE CONCENTRATIONS THROUGHOUT ADULTHOOD [J].
ORENTREICH, N ;
BRIND, JL ;
RIZER, RL ;
VOGELMAN, JH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 59 (03) :551-555
[44]  
Petri M., 1997, Arthritis and Rheumatism, V40, pS327
[45]   DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters [J].
Rabkin, JG ;
Ferrando, SJ ;
Wagner, GJ ;
Rabkin, R .
PSYCHONEUROENDOCRINOLOGY, 2000, 25 (01) :53-68
[46]   Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16α-fluoro-5-androsten-17-one and its reversal by NADPH liposomes [J].
Schwartz, AG ;
Pashko, LL .
CANCER LETTERS, 2001, 168 (01) :7-14
[47]  
SCHWARTZ AG, 1989, CARCINOGENESIS, V10, P1809
[48]   Scientific verdict still out on DHEA [J].
Skolnick, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17) :1365-1367
[49]   A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy [J].
Sugino, M ;
Ohsawa, N ;
Ito, T ;
Ishida, S ;
Yamasaki, H ;
Kimura, F ;
Shinoda, K .
NEUROLOGY, 1998, 51 (02) :586-589
[50]   Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: Possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy [J].
Tsuji, K ;
Furutama, D ;
Tagami, M ;
Ohsawa, N .
LIFE SCIENCES, 1999, 65 (01) :17-26